AU2119695A - Synergistic inhibition of hiv-1 infection using a nucleoside reverse transcriptase inhibitor and anti-hiv-1 antibodies - Google Patents

Synergistic inhibition of hiv-1 infection using a nucleoside reverse transcriptase inhibitor and anti-hiv-1 antibodies

Info

Publication number
AU2119695A
AU2119695A AU21196/95A AU2119695A AU2119695A AU 2119695 A AU2119695 A AU 2119695A AU 21196/95 A AU21196/95 A AU 21196/95A AU 2119695 A AU2119695 A AU 2119695A AU 2119695 A AU2119695 A AU 2119695A
Authority
AU
Australia
Prior art keywords
hiv
antibodies
infection
reverse transcriptase
nucleoside reverse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21196/95A
Inventor
Nancy T. Chang
Michael S. C Fung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of AU2119695A publication Critical patent/AU2119695A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU21196/95A 1994-03-16 1995-03-14 Synergistic inhibition of hiv-1 infection using a nucleoside reverse transcriptase inhibitor and anti-hiv-1 antibodies Abandoned AU2119695A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21483794A 1994-03-16 1994-03-16
PCT/US1995/003169 WO1995024904A1 (en) 1994-03-16 1995-03-14 Synergistic inhibition of hiv-1 infection using a nucleoside reverse transcriptase inhibitor and anti-hiv-1 antibodies
US214837 2002-08-08

Publications (1)

Publication Number Publication Date
AU2119695A true AU2119695A (en) 1995-10-03

Family

ID=22800604

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21196/95A Abandoned AU2119695A (en) 1994-03-16 1995-03-14 Synergistic inhibition of hiv-1 infection using a nucleoside reverse transcriptase inhibitor and anti-hiv-1 antibodies

Country Status (2)

Country Link
AU (1) AU2119695A (en)
WO (1) WO1995024904A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893124A1 (en) * 1997-07-24 1999-01-27 Roche Diagnostics GmbH Pharmaceutical combination preparations comprising human monoclonal antibodies for the treatment of chronic hepatitis B and a virostatic substance
AU1759501A (en) * 1999-11-08 2001-06-06 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Method of treating a viral infection using antagonists of macrophage colony stimulating factor
EP1373318A2 (en) * 2001-01-26 2004-01-02 Abgenix, Inc. Neutralizing human monoclonal antibodies against hiv-1, their production and uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086044A (en) * 1986-06-23 1992-02-04 Burroughs Wellcome Co. Treatment of human viral infections
US5266478A (en) * 1987-05-29 1993-11-30 Tanox Biosystems, Inc. Antibodies which target a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
US5245015A (en) * 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
AU9072991A (en) * 1990-10-26 1992-05-26 Public Health Research Institute Of The City Of New York, Inc., The Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination

Also Published As

Publication number Publication date
WO1995024904A1 (en) 1995-09-21

Similar Documents

Publication Publication Date Title
AU641769B2 (en) Inhibitors of HIV reverse transcriptase
AU2216292A (en) Inhibitors of hiv reverse transcriptase
AU1694295A (en) Benzoxazinones as inhibitors of hiv reverse transcriptase
HU9502468D0 (en) Inhibitors of hiv reverse transcriptase
SG80631A1 (en) Inhibitors of hiv reverse transcriptase
AU8596191A (en) Hydroxylated inhibitors of hiv reverse transcriptase
AU8693491A (en) Synergism of hiv reverse transcriptase inhibitors
AU2436792A (en) Quinazoline derivatives as inhibitors of hiv reverse transcriptase
AU1046895A (en) New quinazolines as inhibitors of hiv reverse transcriptase
AU1539699A (en) Methods for treatment of hiv or other infections using a t cell or viral activator and anti-retroviral combination therapy
AU5850894A (en) Novel agents for inhibition of hiv infectivity and use therefor
AU2119695A (en) Synergistic inhibition of hiv-1 infection using a nucleoside reverse transcriptase inhibitor and anti-hiv-1 antibodies
AU3841393A (en) New quinazolines as inhibitors of HIV reverse transcriptase
HUT77573A (en) Composition for prevention and treatment of hiv-1 infection comprising at least two different hiv-1 reverse transcriptase inhibitors
AU7666496A (en) Structure based design of inhibitors of hiv-1 reverse transcriptase
BR9607714A (en) Combination of compound processes to inhibit hiv protease and hiv reverse transcriptase and to prevent hiv infection or to treat hiv infection or to treat aids or arc and pharmaceutical composition
AU6962894A (en) Compositions and methods for inhibiting replication of human immunodeficiency virus-1
AU7845191A (en) Inhibitors of HIV reverse transcriptase
AU3299199A (en) Compositions for inhibiting human immunodeficiency virus using hydroxyurea and areverse transcriptase inhibitor
AU6355296A (en) Use of a non-nucleoside reverse transcriptase inhibitor in a ssociation with nucleoside inhibitors for the treatment of h iv infection
AU2143292A (en) Peptidomimetic inhibitors of hiv gp120 binding to cd4
EP0308977A3 (en) Anthracycline derivatives having inhibitory activity against reverse transcriptase of human immunodeficiency virus
GB9308781D0 (en) Inhibitors of hiv reverse transcriptase
AU1189899A (en) Inhibition of human immunodeficiency virus (hiv-1) replication
ZA914653B (en) Inhibitors of hiv reverse transcriptase